Biopharma Application Of Micell Technology
Drug delivery systems are disclosed which include a drug in dry powder form and a biodegradable or metabolizable carrier having an average particle size of less than about 1 mm for delivery of the drug to a particular location in the body and for providing for the timed elution of the drug at that location, preferably by exhibiting a linear drug elution profile for a sustained drug release period of at least 30 days. Methods for manufacturing these drug delivery systems are also disclosed.
1 . A method for manufacturing a drug delivery system comprising:
providing a biodegradable or metabolizable carrier, and applying a drug in dry powder form to said carrier, whereby said drug delivery system can be delivered to a predetermined location in the body of a patient, and thereby provide for the timed elution of said drug to said predetermined location.
2 . The method of claim 1 , wherein said timed elution of said drug comprises a linear drug release profile, and has a sustained drug release of at least 30 days.
3 . The method of claim 2 , wherein said timed elution of said drug has a sustained drug release of at least 60 days.
4 . The method of claim 3 , wherein said timed elution of said drug has a sustained drug release of at least 90 days.
5 . The method of claim 1 , wherein said applying of said drug comprises delivering said drug to said carrier by means of a compressed gas.
6 . The method of claim 5 , wherein said drug and said carrier are admixed after said delivery of said drug to said carrier.
7 . The method of claim 5 , wherein said drug is applied to said carrier as a coating.
8 . The method of claim 5 , wherein said carrier is provided by delivering said carrier by means of a compressed gas.
9 . The method of claim 1 , wherein said carrier is provided by delivering said carrier by means of a compressed gas.
10 . The method of claim 1 , wherein said drug is at least partially crystalline
11 . The method of claim 1 , wherein said drug delivery system comprises an implant, an intravenous composition, a coated substrate, and injectable depot formulation or an orally-ingestable composition.
12 . The method of claim 11 , wherein said intravenous composition comprises a plurality of microparticles.
13 . The method of claim 11 , wherein said intravenous composition comprises a plurality of particles having a particle size of less than about 10 μm.
14 . The method of claim 11 , wherein said injectable depot formulation comprises a plurality of particles having a particle size of between about 30 and 1,000 μm.
15 . The method of claim 14 , wherein said plurality of particles comprises a plurality of rod-like particles.
16 . The method of claim 11 , wherein said orally-ingestable composition comprises a tablet, capsule, pill, or caplet.